The total sale represents 7.3% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

A new survey* conducted by Haleon, a global leader in consumer health, reveals a significant public health concern in Malaysia: tooth sensitivity. The survey of 248 Malaysians showed that a staggering ...

Haleon was formed in 2022 from a combination of GSK and Pfizer’s consumer-health units. Pfizer has been cutting down its stake in Haleon, most recently raising £2.5 billion through a block ...

Haleon was a consumer health joint venture (JV), an over-the-counter (OTC) medicines business jointly created by Pfizer and GSK plc. GSK in 2019. GSK owned a controlling stake of 68% in the ...

Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, created in a merger of GSK and Pfizer's consumer healthcare businesses in 2019, and spun off in 2022. Under the deal ...

In context, Haleon was created in July 2019 through the merger of GlaxoSmithKline’s (GSK) and Pfizer’s consumer healthcare divisions. In July 2022, GSK spun off Haleon as an independent public ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer. Haleon floated on the London Stock Exchange with a value of ...

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...